[REVISION HISTORY]

Cardiac amyloidosis awareness and diagnostic initiatives

4 recorded revisions of this situation.

What changed

2026-10-29 17:06 UTC → 2026-10-29 18:19 UTC · added ~~removed~~

Efforts to improve the detection and awareness of transthyretin cardiac amyloidosis (ATTR-CM) have emerged through national and corporate campaigns in Europe. In France, medical societies and patient associations launched the ‘Chameleon Disease’ campaign to address the frequent misidentification of the condition. Because symptoms often mimic rheumatological or orthopedic issues, diagnosis typically occurs two to four years after symptoms appear. A national screening program involving nearly 50 hospital centers was scheduled to begin on October 26 to improve early detection, which can increase survival chances by 40%. Coinciding with World Cardiac Amyloidosis Day on October 26, Bayer launched the ‘A tuTTo cuoRe’ awareness campaign in Italy. ~~This initiative focuses on educating the public about the progressive nature of ATTR-CM, where protein filaments reduce the heart’s pumping efficiency.~~ Building on these efforts, medical professionals and scientific societies have emphasized the necessity of personalized medicine. During recent conferences in Rome, experts including Marco Merlo and Laura Obici highlighted that genetic testing is vital to dictate therapeutic strategies and patient monitoring. This is essential for distinguishing between hereditary and non-hereditary forms. ~~In a broader discussion on rare diseases, Italian health officials and specialists have called for enhanced diagnostic and therapeutic strategies. Marcello Gemmato, Undersecretary~~ During the International Day of ~~Health,~~ Rare Bone Diseases, stakeholders in Rome further emphasized the need for ~~early diagnosis~~ multidisciplinary care and ~~equitable~~ improved access to ~~therapies to mitigate social~~ orphan drugs. Specialists underscored that genetic testing remains critical for implementing precision medicine and ~~economic impacts. Experts~~ monitoring at-risk family members. Discussions also addressed the need to include screenings in the Essential Levels of Assistance (LEA) to reduce regional healthcare disparities. Furthermore, officials noted that ~~bone diseases account for over 10%~~ only approximately 5% of ~~rare diseases in Italy, and advocates continue~~ patients have access to ~~push for multidisciplinary care, specialized registries, and improved medical training~~ specific cures, often leaving them reliant on unregulated supplements. The Military Chemical-Pharmaceutical Establishment in Florence was identified as a potential centralized importer to ensure ~~early detection across various rare conditions.~~ standardized quality for therapeutic products.

Versions

Select a version to see what changed compared to the one before it.